Presentation of results for first quarter 2013

DiaGenic will present results for the first quarter 2013 on Wednesday 15 May 2013. Interim report and presentation slides will be posted on www.newsweb.no and on DiaGenic’s web page: www.diagenic.com on 15 May at approximately 08:00 CET.

A conference call for a presentation of the results is scheduled the same day at 12:00 CET. Please use the dial-in details listed below, corresponding to your location, to participate in the conference call. The conference ID is: 6873001

Participant Access - Dial in 5-10 minutes prior to the start of the call using one of the numbers below

Confirmation   Code: 6873001
  Participants,    Local - Oslo, Norway: +472350 0486
  Participants,    Local - Stockholm, Sweden: +46(0)8 5876   9446
  Participants,    Local - Copenhagen, Denmark: +4538 32 28 69
  Participants,    Local - New York, United States of America: +1718 354   1158
  Participants,    Local - London, United Kingdom: +44(0)20 3427   1919

Please use the Direct Access link below to follow the presentation slides:

Adobe Connect Web Meeting:
To be entered directly into your Adobe Connect web meeting click on the Direct Access Link:
 

  http://webmeeting.adobeconnect.com/e6873001

 
 
 
  Need Help? Contact Customer Support:
  Phone:   +353 (0) 23 88 32131
  E-Mail:   euvisioncast@premiereglobal.ie
 
 

Contact:

Paul de Potocki, Chief Executive Officer

Telephone: 47 2324 8950

e-mail: paul.depotocki@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.

Subscribe